Increases in human epidermal DR+CD1+, DR+CD1-CD36+, and DR-CD3+ cells in allergic versus irritant patch test responses.
In an attempt to differentiate an allergic patch test response from an irritant response, we evaluated by flow cytometry the percentages of various epidermal cell populations isolated from allergen and irritant-treated patch test sites. Nine allergic individuals were patch tested with various allergens (Rhus, dinitrochlorobenzene [DNCB], or nickel chloride) and a vehicle control for 48 h. Eight additional individuals were patch tested with irritating chemicals (sodium lauryl sulfate or nonanoic acid) and with a vehicle control for 48 h. Epidermal cells, isolated from suction blisters, were double labeled for CD1/HLA-DR, CD3/HLA-DR, or CD36/HLA-DR cell surface markers and analyzed by flow cytometry to determine the percentage of various cell populations. A mean increase of 0.91 +/- 0.3 in the percentage of DR+CD1+ Langerhans cells over the vehicle control patch test site was detected in allergen-positive patch test sites in allergic individuals, whereas a decrease of 0.19 +/- 0.2 in the percentage of DR+CD1+ Langerhans cells from the vehicle control patch test site was detected in irritant-treated patch test sites. Epidermal cells from allergen-positive patch test sites also exhibited an increase of 5.2 +/- 1.8 in percentage of DR+CD1- cells over the vehicle control patch test site compared to an increase change of 0.8 +/- 0.4 in epidermal cells isolated from irritant-treated patch test sites. We also found that DR+ cells that lacked the CD1 determinant expressed the macrophage/monocyte antigen CD36 (OKM5). Finally, a 2.3 +/- 0.8 increase in the percentage of DR-CD3+ cells over the vehicle control patch test site was observed in allergen-positive patch test sites compared to an increase of 0.2 +/- 0.2 observed in irritant-treated patch test sites. These results demonstrate a significant increase in DR+CD1+, DR+CD1-CD36+, and DR-CD3+ epidermal cells in allergen-positive patch test sites compared to irritant patch test sites.
Gerberick
G F
GF
Procter and Gamble Co., Miami Valley Laboratories, Cincinnati, OH 45239-8707.
Rheins
L A
LA
Ryan
C A
CA
Ridder
G M
GM
Haren
M
M
Miller
C
C
Oelrich
D M
DM
von Bargen
E
E
D000328:Adult; D000485:Allergens / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis*; D018949:Antigens, CD1; D017252:CD3 Complex / Q000032:analysis*; D018955:CD36 Antigens; D017453:Dermatitis, Irritant / Q000276:immunology; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000166:cytology* / Q000276:immunology*; D012882:Skin Tests
D000485:Allergens; D015703:Antigens, CD; D018949:Antigens, CD1; D017252:CD3 Complex; D018955:CD36 Antigens; D006684:HLA-DR Antigens